Home Tags Enfortumab vedotin

Tag: enfortumab vedotin

Featured Image: Doctor explaining diagnosis to her patient Courtesy: © 2017 Fotolia. Used with permission.

Phase Ib Trial of Enfortumab Vedotin + Immune Checkpoint Inhibitor Initiated...

Seattle Genetics and Astellas Pharma confirmed the dosing of the first patient in EV-103, a phase Ib clinical trial evaluating the safety and tolerability...

Seattle Genetics and Astellas Pharma Evaluate Enfortumab Vedotin as Monotherapy in...

Seattle Genetics and Astellas Pharma today confirmed dosing the first patient in EV-201, a registrational phase II clinical trial of enfortumab vedotin as a...

Winding-Down of Research Operations but Astellas Retains Promising Antibody-Drug Conjugate R&D...

In a surprise move to most, but expected by industry insiders, Astellas Pharma, a Japan-based company focusing on the development of novel treatments in Urology,...

Phase I Data of Enfortumab Vedotin in Metastatic Urothelial Cancer Supports...

Updated phase I data for enfortumab vedotin, also known as ASG-22ME or ASG-22CE , studied as monotherapy treatment for metastatic urothelial cancer (mUC) were...

Promising Phase I Data for Enfortumab Vedotin (ASG-22ME) and ASG-15ME in...

The annual congress of the European Society of Medical Oncology (ESMO), this year held in Copenhagen, Denmark (October 7 - 11, 2016) is the premier...

Clinical Phase I Data for ASG-15ME and Enfortumab Vedotin (ASG-22ME) Indicates...

Clinical data for ASG-15ME and Enfortumab vedotin, also known as ASG-22ME and ASG-22M6E,  presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting held June...

Astellas Presents Study-results of two Investigational ADCs in Patients with Metastatic...

With two approved antibody-drug conjugates and a large number of  ADCs in clinical development scientists have made significant advances bringing novel ADC technology to the forefront...

Clinical Updates Confirming Advances and Meaningful Benefits for Patients

Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...

ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...

Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...